false 0001763950 0001763950 2024-06-13 2024-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 13, 2024

 

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39318   46-3973463

(State or Other Jurisdiction

of Incorporation)

   (Commission
File Number)		  

(IRS Employer

Identification No.)

 

1920 McKinney Avenue, 7th Floor

Dallas, Texas

   75201
(Address of Principal Executive Offices)   (Zip Code)

 

(972) 277-1136

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: Common Stock

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value   LTRN   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 13, 2024, Lantern Pharma Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders, for the purposes of:

 

  ● Electing five directors, each to serve until our 2025 Annual Meeting of Stockholders;
     
●Approving an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended (the “Equity Incentive Plan “) to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 125,000 shares; and
   
  ● Ratifying the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

 

All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, and David S. Silberstein, were elected to our board of directors, with shares voted as follows:

 

Name  For   Withheld  

Broker

Non-Vote

 
Donald Jeff Keyser   3,039,380    21,849    4,225,984 
Panna Sharma   3,038,303    22,926    4,225,984 
Vijay Chandru   3,030,488    30,741    4,225,984 
Maria Maccecchini   3,038,407    22,822    4,225,984 
David S. Silberstein   3,038,877    22,352    4,225,984 

 

Our stockholders approved an amendment to the Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 125,000 shares, with shares voted as follows:

 

For   2,892,948 
Against   128,312 
Abstain   39,969 
Broker Non-Votes   4,225,984 

 

In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024, with shares voted as follows:

 

For   7,169,506 
Against   39,941 
Abstain   77,766 

 

There were no broker non-votes on the ratification of our independent registered public accounting firm.

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Lantern Pharma Inc.,
  A Delaware Corporation
   
Dated: June 17, 2024 By: /s/ David R. Margrave
    David R. Margrave, Chief Financial Officer

 

3

 

v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity File Number 001-39318
Entity Registrant Name Lantern Pharma Inc.
Entity Central Index Key 0001763950
Entity Tax Identification Number 46-3973463
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1920 McKinney Avenue
Entity Address, Address Line Two 7th Floor
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75201
City Area Code (972)
Local Phone Number 277-1136
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol LTRN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Grafico Azioni Lantern Pharma (NASDAQ:LTRN)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Lantern Pharma
Grafico Azioni Lantern Pharma (NASDAQ:LTRN)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Lantern Pharma